SCHEMBL24837880

SCHEMBL24837880

C[C@@H]1c2c([nH]c3nnc(-c4ccccc4O)cc23)CCN1C1CCN(C2CCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 2/20 0.46
▸ SMARCA4 P51532 2/20 0.46
▸ PBRM1 Q86U86 2/20 0.46
▸ PARP1 P09874 2/20 0.40
▸ PRKCG P05129 1/20 0.36
▸ PRKCB P05771 1/20 0.36
▸ PRKCA P17252 1/20 0.36
▸ PRKCH P24723 1/20 0.36
▸ PRKCE Q02156 1/20 0.36
▸ PRKCD Q05655 1/20 0.36
▸ OPRM1 P35372 1/20 0.36
▸ OPRD1 P41143 1/20 0.36
▸ OGFRL1 Q5TC84 1/20 0.36
▸ ACACB O00763 1/20 0.35
▸ ACACA Q13085 1/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ PIM2 Q9P1W9 1/20 0.35
▸ GPR119 Q8TDV5 3/20 0.34
▸ STS P08842 1/20 0.34
▸ CCNT1 O60563 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30179121 1.00 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1PARP1PRKCG
SCHEMBL30179227 1.00 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1PARP1PRKCG
SCHEMBL30178884 1.00 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1PARP1PRKCG
SCHEMBL30178957 1.00 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1PARP1PRKCG
SCHEMBL24838421 1.00 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1PARP1PRKCG
SCHEMBL24838350 1.00 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1PARP1PRKCG
SCHEMBL24838437 1.00 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1PARP1PRKCG
SCHEMBL24838737 1.00 SMARCA2 (0.46) SMARCA2SMARCA4PBRM1PARP1PRKCG
SCHEMBL24837891 0.98 SMARCA2 (0.45) SMARCA2SMARCA4PBRM1PARP1PRKCG
SCHEMBL24838750 0.98 SMARCA2 (0.45) SMARCA2SMARCA4PBRM1PARP1PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-08 — — US disclosed
WO-2023278402-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230173078-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 SMARCA2 2/4885SMARCA4 8/4885PBRM1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback